We saw a spate of funding deals and other activity in the week or so preceding Thanksgiving. Here’s our roundup of life sciences news, with best wishes from Xconomy for your Thanksgiving holiday.
—Allergan (NYSE: AGN), the Irvine, CA-based multi-specialty healthcare company, said it has agreed to pay $350 million upfront to buy the skin care business from Carlsbad, CA-based SkinMedica. The deal will expand Allergan’s line of skin-care products, which includes the wrinkle reducer Botox and skin filler Juvederm. SkinMedica’s products include Vaniqa, the only prescription product for reducing unwanted facial hair in women. Allergan said it will pay an extra $25 million if certain sales goals are met. The deal doesn’t include SkinMedica’s Colorescience makeup line, which will be spun out as a separate company
—San Diego’s Vital Therapies has extended its latest round to $86.1 million, according to a regulatory filing made earlier this month. The company, which is developing a product that combines liver cells with a medical device that could help people with acute liver failure, said in September that it planned to raise $76 million from existing investors. At the time, Vital Therapies said the capital would be used to … Next Page »